Department of Operative Medicine, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
Langenbecks Arch Surg. 2010 Jan;395(1):73-80. doi: 10.1007/s00423-009-0545-1. Epub 2009 Aug 25.
To perform focused or minimally invasive surgery for hyperparathyroidism (HPT) exact preoperative localization is mandatory. Computed tomography-(99m)Tc-sestamibi-single photon emission computed tomography image fusion (CT-MIBI-SPECT) serves this difficult task in single gland HPT to a large extent. The aim of this study was to evaluate whether CT-MIBI-SPECT image fusion is superior to MIBI-SPECT alone and CT alone in detecting abnormal parathyroid tissue in patients with multiglandular disease.
CT-MIBI-SPECT image fusion for preoperative localization was performed in 30 patients with multiglandular disease. There were six patients with primary hyperparathyroidism (four MEN I syndromes and two double adenomas; one of these patients has HRPT2 gene mutation), 14 with secondary, and eight with tertiary HPT, further one patient each suffering from persistent primary and persistent secondary hyperparathyroidism. In both persistent patients only one remaining gland was left from primary surgery. The results of MIBI-SPECT, CT, and CT-MIBI-SPECT image fusion were compared in these patients. The outcome and the exact predicted positions were correlated with intraoperative findings.
In five out of six patients with multiglandular primary hyperparathyroidism more than one gland was detected, thus multiglandular disease could be suspected preoperatively. Overall CT-MIBI-SPECT image fusion was able to predict the exact position of all abnormal glands per patient in 14 of 30 (46.7%) cases, whereas CT alone was successful in 11 (36.7%), and MIBI-SPECT alone just in four (13.3%) of 30 patients.
Multiglandular disease in primary hyperparathyroidism can be suspected preoperatively in a high percentage of patients. Additionally, this study shows that CT-MIBI-SPECT image fusion is superior to CT or MIBI-SPECT alone in preoperative localization of all pathologic glands in patients suffering from multiglandular disease.
为了对甲状旁腺机能亢进症(HPT)进行针对性或微创手术,术前精确定位是必须的。计算机断层扫描-(99m)Tc- sestamibi-单光子发射计算机断层扫描图像融合(CT-MIBI-SPECT)在单腺 HPT 中在很大程度上完成了这项困难的任务。本研究旨在评估 CT-MIBI-SPECT 图像融合在检测多腺体疾病患者异常甲状旁腺组织方面是否优于 MIBI-SPECT 单独和 CT 单独。
对 30 例多腺体疾病患者进行了 CT-MIBI-SPECT 图像融合术术前定位。原发性甲状旁腺机能亢进症(甲状旁腺机能亢进症)有 6 例(MEN I 综合征 4 例,双腺瘤 2 例;其中 1 例患者 HRPT2 基因突变),继发性甲状旁腺机能亢进症 14 例,三发性甲状旁腺机能亢进症 8 例,持续性原发性甲状旁腺机能亢进症和持续性继发性甲状旁腺机能亢进症各 1 例。在这两个持续的患者中,原发性手术后只剩下一个腺体。比较了 MIBI-SPECT、CT 和 CT-MIBI-SPECT 图像融合在这些患者中的结果。将结果和准确预测的位置与术中发现相关联。
在 6 例多腺体原发性甲状旁腺机能亢进症患者中,有 5 例发现了不止一个腺体,因此术前可以怀疑有多腺体疾病。总体而言,CT-MIBI-SPECT 图像融合能够预测每位患者的所有异常腺体的精确位置,30 例患者中有 14 例(46.7%),而 CT 单独成功的有 11 例(36.7%),MIBI-SPECT 单独成功的只有 4 例(13.3%)。
在原发性甲状旁腺机能亢进症患者中,多腺体疾病可以在很高的百分比的患者中被怀疑。此外,本研究表明,在多腺体疾病患者中,CT-MIBI-SPECT 图像融合在术前定位所有病理腺体方面优于 CT 或 MIBI-SPECT 单独。